FDA Proposal Threatens Transparency on Cancer Drug Safety and Efficacy
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that.
Chronic Myeloid Leukemia
CHRONIC MYELOID LEUKEMIA ADVISOR
FEATURED CONTENT
-
-
Everyone’s Conflicted: How Open Payments Did Little to Discourage Conflicts of Interest in Oncology
Since its inception, the Open Payments act does not appear to have prompted physicians to accept fewer payments from industry overall. -
The Disappointing Reality of Crowdfunding Cancer Care
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity. -
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed. -
Pathologists Need Better Reporting Guidelines for Postneoadjuvant Chemotherapy Specimens
Measuring a tumor’s response to neoadjuvant chemotherapy can be prognostic, providing important clues about a patient’s likely outcome following treatment.
VIDEO SERIES
Ponatinib for CML
Progress in the CML Landscape
Treatment Options
Sequencing Treatment
Choosing the Appropriate TKI
Monitoring Treatment Response
Monitoring Adherence
Switching Therapies
Discontinuing Treatment
Known Factors in TKI Resistance
Managing Adverse Events
Allogeneic Stem Cell Transplant
CML: On the Horizon
The Future of CML Treatment
CHRONIC MYELOID LEUKEMIA NEWS
Adherence to Other Oral Medications Declines Following Introduction of Oral Oncolytics
Follow-Up Results of Low-Dose Dasatinib for Chronic-Phase Chronic Myeloid Leukemia
Blast Count Prognostic for CML Presenting in Advanced Phase
Study Compares Quality of Life for Patients With Chronic Myeloid Leukemia Treated With Dasatinib vs Imatinib
Outcomes With Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Want to read more?
Please login or register first to view this content.
Next post in Chronic Myeloid Leukemia
